158 results
Page 5 of 8
SC TO-T/A
EX-99
7o46hyi
19 Jan 12
Third party tender offer statement (amended)
12:00am
SC TO-T
EX-99
vvpg4r92
13 Jan 12
Third party tender offer statement
12:00am
SC TO-T
EX-99
tspd0afm 0x7fzg
13 Jan 12
Third party tender offer statement
12:00am
8-K
EX-99.1
ouh 9oplb5fgwxexnl
9 Jan 12
Bristol-Myers Squibb to Acquire Inhibitex
12:00am
8-K
EX-99.1
kqy5ayez4g2wwq 55
27 Oct 11
Bristol-Myers Squibb Delivers Strong Third Quarter with Important Clinical Data, Solid Operating Results and Continued Focus on Business Development
12:00am
8-K
EX-99.1
0zdyt8lbfcj95xfjetv
28 Jul 11
Important Clinical Data and Strong Financial Results
12:00am
8-K
EX-99.1
78qze2m9y4z
27 Jan 11
Receives U.S. Regulatory Approval for KOMBIGLYZE™ XR, and First-Line Indication for SPRYCEL® in Fourth Quarter
12:00am
8-K
EX-99.1
81z2wcmma 5vzjqws
26 Oct 10
Robust Clinical Data and the Strategic Acquisition of ZymoGenetics
12:00am
SC TO-T/A
EX-99
2dzvsc5
29 Sep 10
Third party tender offer statement (amended)
12:00am
SC TO-T/A
EX-99
hw3yo
13 Sep 10
Third party tender offer statement (amended)
12:00am
8-K
EX-99.1
m5tahpnq
22 Jul 10
Bristol-Myers Squibb Second Quarter Featured Robust Clinical Data
12:00am